Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry

BACKGROUND: Pragmatic use of the anti-fibrotic medications pirfenidone and nintedanib for idiopathic pulmonary fibrosis (IPF) in the United States (US) has not been studied and may be different from international settings due to structural differences between health care systems. This study examined...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Respir Res
Päätekijät: Holtze, Colin H., Freiheit, Elizabeth A., Limb, Susan L., Stauffer, John L., Raimundo, Karina, Pan, Wayne T., Flaherty, Kevin R., Kim, Hyun J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2020
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7011239/
https://ncbi.nlm.nih.gov/pubmed/32041621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-020-1315-4
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia